drugset / Trial / NCT05781906

Human Mass Balance of [14C]HMPL-523 in Healthy Adult Male Chinese Subjects

NCT05781906

Phase 1 Completed 6 enrolled Hutchmed
NaSequentialOpen-labelHealth-services research

Summary

To evaluate the absorption, metabolism and excretion of HMPL-523 in healthy male Chinese subjects following multiple oral doses of HMPL-523 tablets followed by a single oral dose of \[14C\]HMPL-523 suspension

Timeline

Start
2023-02-08
Primary completion
2023-06-01
Completion
2023-12-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Sovleplenib Small molecule 300 mg Oral